NCT00555971.

Trial name or title	Therapeutic utility of Xolair in patients undergoing aspirin desensitisation
Methods	Randomised, double‐blind, parallel‐group study
Participants	Patients with aspirin‐exacerbated respiratory disease 18 years of age or older
Interventions	Dosage (150 to 375 mg) based on IgE levels; administered subcutaneously every two to four weeks for 16 weeks versus placebo
Outcomes	FEV1 and changes in serum and urinary markers of eosinophil activation during desensitisation and change in urinary LTE4 during bronchospasm
Starting date	May 2006
Contact information	http://clinicaltrials.gov/ct2/show/NCT00555971
Notes